Pathological Controversies in Breast Cancer: Classification of Ductal Carcinoma In Situ, Sentinel Lymph Nodes and Low Volume Metastatic Disease and Reporting of Neoadjuvant Chemotherapy Specimens

Clinical Oncology

Volumn 25, Issue 2, 2013, Pages 80-92

  Provenzano, E ^a,b   Brown, J P ^c   Pinder, S E ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Focus Pathology   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; Ductal carcinoma in situ; Histopathology; Neoadjuvant chemotherapy; Sentinel lymph nodes

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADJUVANT CHEMOTHERAPY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CELL STRUCTURE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17Q; CYTOLOGY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FOLLOW UP; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; MASTECTOMY; META ANALYSIS (TOPIC); MICROMETASTASIS; MOLECULAR BIOLOGY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR NECROSIS; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; SENTINEL LYMPH NODE BIOPSY;

EID: 84872369525     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.10.008     Document Type: Article

References (109)

1. National Health Service Pathology reporting of breast disease 2005, NHS Cancer Screening Programmes, Sheffield. 3rd ed.
2. Pinder S.E., Duggan C., Ellis I.O., et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer 2010, 103(1):94-100.
3. Poller D.N., Silverstein M.J., Galea M., et al. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 1994, 7(2):257-262.
4. Bijker N., Meijnen P., Peterse J.L., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006, 24(21):3381-3387.
5. Fisher B., Dignam J., Wolmark N., et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998, 16(2):441-452.
6. Houghton J., George W.D., Cuzick J., Duggan C., Fentiman I.S., Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362(9378):95-102.
7. Dodwell D., Clements K., Lawrence G., et al. Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ: indications and utilisation in the UK. Interim findings from the Sloane Project. Br J Cancer 2007, 97(6):725-729.
8. Silverstein M.J., Lagios M.D. Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr 2010, 2010(41):193-196.
9. Ellsworth R.E., Ellsworth D.L., Love B., et al. Correlation of levels and patterns of genomic instability with histological grading of DCIS. Ann Surg Oncol 2007, 14(11):3070-3077.
10. Lopez-Garcia M.A., Geyer F.C., Lacroix-Triki M., Marchio C., Reis-Filho J.S. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010, 57(2):171-192.
11. Buerger H., Otterbach F., Simon R., et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast - evidence of multiple genetic pathways. J Pathol 1999, 187(4):396-402.
12. Johnson C.E., Gorringe K.L., Thompson E.R., et al. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma. Breast Cancer Res Treat 2012, 133(3):889-898.
13. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
14. Curtis C., Shah S.P., Chin S.F., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486(7403):346-352.
15. Clark S.E., Warwick J., Carpenter R., Bowen R.L., Duffy S.W., Jones J.L. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 2011, 104(1):120-127.
16. Dabbs D.J., Chivukula M., Carter G., Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 2006, 19(11):1506-1511.
17. Livasy C.A., Perou C.M., Karaca G., et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007, 38(2):197-204.
18. Vincent-Salomon A., Lucchesi C., Gruel N., et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008, 14(7):1956-1965.
19. Altintas S., Toussaint J., Durbecq V., et al. Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS). Breast J 2011, 17(4):343-351.
20. Shin S.J., Simpson P.T., Da Silva L., et al. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. Am J Surg Pathol 2009, 33(4):496-504.
21. Polyak K., Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2010, 2(11):a003244.
22. Polyak K. Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010, 2010(41):210-213.
23. Toussaint J., Durbecq V., Altintas S., et al. Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS One 2010, 5(8).
24. Patani N., Mokbel K. Clinical significance of sentinel lymph node isolated tumour cells in breast cancer. Breast Cancer Res Treat 2011, 127(2):325-334.
25. Weaver D.L., Krag D.N., Ashikaga T., Harlow S.P., O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000, 88(5):1099-1107.
26. Chagpar A.B. Clinical significance of minimal sentinel node involvement and management options. Surg Oncol Clin North Am 2010, 19(3):493-505.
27. Cserni G., Gregori D., Merletti F., et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004, 91(10):1245-1252.
28. de Boer M., van Dijck J.A., Bult P., Borm G.F., Tjan-Heijnen V.C. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 2010, 102(6):410-425.
29. Salhab M., Patani N., Mokbel K. Sentinel lymph node micrometastasis in human breast cancer: an update. Surg Oncol 2011, 20(4):e195-e206.
30. Tan L.K., Giri D., Hummer A.J., et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 2008, 26(11):1803-1809.
31. van Deurzen C.H., de Boer M., Monninkhof E.M., et al. Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst 2008, 100(22):1574-1580.
32. Barry M., Kell M.R. Breast cancer: can axillary lymph node dissection be avoided?. Eur J Surg Oncol 2012, 38(1):6-7.
33. Cody H.S., Houssami N. Axillary management in breast cancer: what's new for 2012?. Breast 2012, 21(3):411-415.
34. Giuliano A.E., Hunt K.K., Ballman K.V., et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305(6):569-575.
35. Giuliano A.E., McCall L., Beitsch P., et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010, 252(3):426-432. discussion 32-33.
36. Maibenco D.C., Dombi G.W., Kau T.Y., Severson R.K. Significance of micrometastases on the survival of women with T1 breast cancer. Cancer 2006, 107(6):1234-1239.
37. Hermanek P., Hutter R.V., Sobin L.H., Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999, 86(12):2668-2673.
38. Singletary S.E., Greene F.L., Sobin L.H. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer 2003, 98(12):2740-2741.
39. Cserni G., Bianchi S., Vezzosi V., et al. Variations in sentinel node isolated tumour cells/micrometastasis and non-sentinel node involvement rates according to different interpretations of the TNM definitions. Eur J Cancer 2008, 44(15):2185-2191.
40. Cserni G., Bianchi S., Boecker W., et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 2005, 103(2):358-367.
41. de Mascarel I., MacGrogan G., Debled M., Brouste V., Mauriac L. Distinction between isolated tumor cells and micrometastases in breast cancer: is it reliable and useful?. Cancer 2008, 112(8):1672-1678.
42. Kumar S., Bramlage M., Jacks L.M., et al. Minimal disease in the sentinel lymph node: how to best measure sentinel node micrometastases to predict risk of additional non-sentinel lymph node disease. Ann Surg Oncol 2010, 17(11):2909-2919.
43. Turner R.R., Weaver D.L., Cserni G., et al. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol 2008, 26(2):258-263.
44. van Deurzen C.H., Cserni G., Bianchi S., et al. Nodal-stage classification in invasive lobular breast carcinoma: influence of different interpretations of the pTNM classification. J Clin Oncol 2010, 28(6):999-1004.
45. AJCC cancer staging handbook from the AJCC cancer staging manual 2010, Springer, Chicago. 7th ed. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
46. UICC TNM classification of malignant tumours 2009, John Wiley and Sons, New York. 7th ed. L.H. Sobin, M. Gospodarowicz, C. Wittekind (Eds.).
47. Cserni G., Amendoeira I., Bianchi S., et al. Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions. Eur J Cancer 2011, 47(6):887-894.
48. Cserni G., Amendoeira I., Apostolikas N., et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol 2004, 57(7):695-701.
49. Weaver D.L. Pathological evaluation of sentinel lymph nodes in breast cancer: a practical academic perspective from America. Histopathology 2005, 46(6):702-706.
50. Weaver D.L. Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. Mod Pathol 2010, 23(Suppl. 2):S26-S32.
51. Dowlatshahi K., Fan M., Snider H.C., Habib F.A. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997, 80(7):1188-1197.
52. Giuliano A.E., Hawes D., Ballman K.V., et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011, 306(4):385-393.
53. Liberman L. Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer 2000, 88(5):971-977.
54. Reed W., Bohler P.J., Sandstad B., Nesland J.M. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up. Breast J 2004, 10(3):174-180.
55. Tjan-Heijnen V.C., Buit P., de Widt-Evert L.M., Ruers T.J., Beex L.V. Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 2001, 70(2):81-88.
56. Weaver D.L., Ashikaga T., Krag D.N., et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011, 364(5):412-421.
57. Gobardhan P.D., Elias S.G., Madsen E.V., et al. Prognostic value of lymph node micrometastases in breast cancer: a multicenter cohort study. Ann Surg Oncol 2011, 18(6):1657-1664.
58. Maaskant-Braat A.J., van de Poll-Franse L.V., Voogd A.C., et al. Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Res Treat 2011, 127(1):195-203.
59. Truong P.T., Lesperance M., Li K.H., MacFarlane R., Speers C.H., Chia S. Micrometastatic node-positive breast cancer: long-term outcomes and identification of high-risk subsets in a large population-based series. Ann Surg Oncol 2010, 17(8):2138-2146.
60. Andersson Y., Frisell J., Sylvan M., de Boniface J., Bergkvist L. Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol 2010, 28(17):2868-2873.
61. de Boer M., van Deurzen C.H., van Dijck J.A., et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009, 361(7):653-663.
62. Pepels M.J., de Boer M., Bult P., et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells. Ann Surg 2012, 255(1):116-121.
63. Gobardhan P.D., Elias S.G., Madsen E.V., et al. Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study. Ann Oncol 2009, 20(1):41-48.
64. Hansen N.M., Grube B., Ye X., et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol 2009, 27(28):4679-4684.
65. Montagna E., Viale G., Rotmensz N., et al. Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat 2009, 118(2):385-394.
66. Truong P.T., Vinh-Hung V., Cserni G., Woodward W.A., Tai P., Vlastos G. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer 2008, 44(12):1670-1677.
67. Kuijt G.P., Voogd A.C., van de Poll-Franse L.V., Scheijmans L.J., van Beek M.W., Roumen R.M. The prognostic significance of axillary lymph-node micrometastases in breast cancer patients. Eur J Surg Oncol 2005, 31(5):500-505.
68. Bilimoria K.Y., Bentrem D.J., Hansen N.M., et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009, 27(18):2946-2953.
69. Cox C.E., Kiluk J.V., Riker A.I., et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg 2008, 206(2):261-268.
70. Grube B.J., Giuliano A.E. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol 2001, 20(3):230-237.
71. Straver M.E., Meijnen P., van Tienhoven G., et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 2010, 17(7):1854-1861.
72. Massimino K.P., Hessman C.J., Ellis M.C., Naik A.M., Vetto J.T. Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest. Am J Surg 2012, 203(5):618-622.
73. Park J., Fey J.V., Naik A.M., Borgen P.I., Van Zee K.J., Cody H.S. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg 2007, 245(3):462-468.
74. Weber W.P., Barry M., Stempel M.M., et al. A 10-year trend analysis of sentinel lymph node frozen section and completion axillary dissection for breast cancer: are these procedures becoming obsolete?. Ann Surg Oncol 2012, 19(1):225-232.
75. Galimberti V., Chifu C., Rodriguez Perez S., et al. Positive axillary sentinel lymph node: is axillary dissection always necessary?. Breast 2011, 20(Suppl. 3):S96-S98.
76. Cserni G. Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification. J Clin Pathol 2012, 65(3):193-199.
77. Dawood S., Merajver S.D., Viens P., et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011, 22(3):515-523.
78. Pinder S.E., Provenzano E., Earl H., Ellis I.O. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 2007, 50(4):409-417.
79. Bonadonna G., Veronesi U., Brambilla C., et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990, 82(19):1539-1545.
80. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001, 30:96-102.
81. Bear H.D. Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy. Surg Oncol Clin North Am 2010, 19(3):607-626.
82. Buzdar A.U. Preoperative chemotherapy treatment of breast cancer - a review. Cancer 2007, 110(11):2394-2407.
83. Chollet P., Amat S., Cure H., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002, 86(7):1041-1046.
84. Hennessy B.T., Hortobagyi G.N., Rouzier R., et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005, 23(36):9304-9311.
85. Kuerer H.M., Sahin A.A., Hunt K.K., et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999, 230(1):72-78.
86. Rastogi P., Anderson S.J., Bear H.D., et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008, 26(5):778-785.
87. Symmans W.F., Peintinger F., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25(28):4414-4422.
88. von Minckwitz G., Untch M., Blohmer J.U., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012 Apr 16.
89. Oh J.L., Nguyen G., Whitman G.J., et al. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 2007, 110(11):2420-2427.
90. Aktepe F., Kapucuoglu N., Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology 1996, 29(1):63-67.
91. Carder P. Typing breast cancer following primary chemotherapy. Histopathology 1999, 35(6):584-585.
92. Abrial S.C., Penault-Llorca F., Delva R., et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005, 94(3):255-263.
93. Chollet P., Amat S., Belembaogo E., et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?. Br J Cancer 2003, 89(7):1185-1191.
94. Jeruss J.S., Mittendorf E.A., Tucker S.L., et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008, 26(2):246-252.
95. Ogston K.N., Miller I.D., Payne S., et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003, 12(5):320-327.
96. Marchio C., Sapino A. The pathologic complete response open question in primary therapy. J Natl Cancer Inst Monogr 2011, 2011(43):86-90.
97. Chevallier B., Roche H., Olivier J.P., Chollet P., Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993, 16(3):223-228.
98. Sataloff D.M., Mason B.A., Prestipino A.J., Seinige U.L., Lieber C.P., Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995, 180(3):297-306.
99. Rodenhuis S., Mandjes I.A., Wesseling J., et al. A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 2010, 21(3):481-487.
100. Smith I.C., Heys S.D., Hutcheon A.W., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002, 20(6):1456-1466.
101. Carey L.A., Metzger R., Dees E.C., et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005, 97(15):1137-1142.
102. Jeruss J.S., Mittendorf E.A., Tucker S.L., et al. Staging of breast cancer in the neoadjuvant setting. Cancer Res 2008, 68(16):6477-6481.
103. Gralow J.R., Zujewski J.A., Winer E. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol 2008, 26(5):696-697.
104. Jones R.L., Lakhani S.R., Ring A.E., Ashley S., Walsh G., Smith I.E. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 2006, 94(3):358-362.
105. Mazouni C., Peintinger F., Wan-Kau S., et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007, 25(19):2650-2655.
106. Loya A., Guray M., Hennessy B.T., et al. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer 2009, 115(8):1605-1612.
107. Sakakibara M., Nagashima T., Kadowaki M., et al. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol 2009, 16(9):2470-2478.
108. Generali D., Symmans W.F., Berruti A., Fox S.B. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2011, 2011(43):99-102.
109. Berruti A., Generali D., Kaufmann M., et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr 2011, 2011(43):147-151.